SCHEMBL25754318

SCHEMBL25754318

CC#CC(=O)COCCCNCCCN

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC6 Q9UBN7 1/20 0.41
PAOX Q6QHF9 1/20 0.40
CASP2 P42575 2/20 0.36
CA12 O43570 2/20 0.36
F13A1 P00488 2/20 0.36
CA2 P00918 2/20 0.36
CYP1A2 P05177 2/20 0.36
ALOX15 P16050 2/20 0.36
CA4 P22748 2/20 0.36
CA6 P23280 2/20 0.36
CA5A P35218 2/20 0.36
THPO P40225 2/20 0.36
CA7 P43166 2/20 0.36
CA9 Q16790 2/20 0.36
CA14 Q9ULX7 2/20 0.36
CA5B Q9Y2D0 2/20 0.36
MEN1 O00255 1/20 0.36
CYP2C19 P33261 1/20 0.36
RECQL P46063 1/20 0.36
KMT2A Q03164 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25754329 0.91 PAOX (0.38) HDAC6PAOXCASP2CA12F13A1
SCHEMBL25754332 0.90 HDAC6 (0.32) HDAC6PAOXMEN1KMT2ASMN1; SMN2
SCHEMBL25754333 0.86 KDM4E (0.42) MEN1KMT2AHSD17B10TSHRSMN1; SMN2
SCHEMBL25754320 0.83
SCHEMBL25754209 0.82 CES2 (0.38) PAOX
SCHEMBL25754338 0.82 CYP1A2 (0.34) CYP1A2MEN1CYP2C19RECQLKMT2A
SCHEMBL25754343 0.81 SAT1 (0.37) CYP1A2MEN1CYP2C19RECQLKMT2A
SCHEMBL25754217 0.81 CES2 (0.37) PAOXALOX15MEN1RECQLKMT2A
SCHEMBL25754215 0.81 CES2 (0.37) PAOXALOX15MEN1RECQLKMT2A
SCHEMBL25754211 0.79 CES2 (0.38)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230210999-A1 TARGETED PROTEASE DEGRADATION (TED) PLATFORM EUBULUS BIOTHERAPEUTICS (HONG KONG) LIMITED (HK) 2023-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230210999-A1 TARGETED PROTEASE DEGRADATION (TED) PLATFORM UCHL3, UBE2L3, ADAM33 HDAC6 636/4885PAOX 4139/4885CASP2 483/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.